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Abstract: In this work hydroxypropyl methylcellulose (HPMC) fast-dissolving thin films for oral
administration are investigated. Furosemide (Class IV of the Biopharmaceutical Classification
System) has been used as a model drug for in vitro release tests using three different set-ups:
the Franz cell, the millifluidic flow-through device, and the paddle type dissolution apparatus
(USP II). In order to enable drug incorporation within HPMC films, a multifunctional excipient,
hydroxypropyl-β-cyclodextrin (HP-β-CD) has been included in the formulation, and the influence
of HP-β-CD on film swelling, erosion, and release properties has been investigated. Mathematical
models capable of describing the swelling and release processes from HPMC erodible thin films in
different apparatuses have been developed. In particular, we propose a new model for the description
of drug transport and release in a Franz cell that accounts for the effect of the unavoidable imperfect
mixing of the receptor chamber.
Keywords: erodible thin films; HPMC; cyclodextrins; furosemide; Franz cell; USP II; millifluidic
flow-through device; erosion
1. Introduction
Most oral dosage forms are designed to be swallowed as a single unit delivering a precise dose
of the drug. Recent data suggest that dosage forms are far from optimal for pediatric or geriatric
patients who have difficulties, or are unable to swallow tablet or capsules [1]. The exact incidence
of patients with impaired ability to swallow (i.e., dysphagia) is not exactly known [2]. It is a known
complication of different pathological conditions, such as stroke, dementia, and chronic obstructive
pulmonary disease (COPD), and it is often observed in patients suffering from progressive neurological
diseases (e.g., Parkinson’s disease), and head and neck cancers. Indeed, it is estimated that 20% of
the population have psychological or physiological impairments that prevent them from swallowing
tablets or capsules. Most of these patients are unwilling to take these formulations due to fear of
choking, which results in a high incidence of non-compliance and failure of pharmacological therapies.
The use of alternative oral dosage forms should be carefully considered. Often patients with
dysphagia or their care providers may alter formulations of medication to facilitate swallowing.
Medication administration errors have been identified three times more frequent in patients with
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dysphagia [3]. The administration of crushed tablets and the contents of opened capsules exposes
the patient to the unpleasant taste of the drug and potentially reduced efficacy of the medication.
To overcome these issues, there are new and improved methods to deliver drugs to the oral cavity [4].
One such novel approach is represented by fast dissolving oral thin films (OTFs) able to increase
consumer acceptance by rapid disintegration, self-administration without the need for drinking or
chewing [5,6].
OTFs, or oral strips, are a stamp-size dosage form that employs a water-soluble polymer,
which allows the dosage form to quickly hydrate by saliva, adhere to mucosa, rapidly disintegrate,
and dissolve in the mouth, thus releasing the drug for both oromucosal and intestinal absorption.
These aspects make them an alternative and more convenient solid dosage form, especially for
patients with swallowing problems. In fact, OTFs can solve the issues related to tablets and capsules,
while guaranteeing the benefits related to solid-dosage forms and, for these reasons, they are gaining
increasing interest.
Hydroxypropyl methylcellulose, also named hypromellose (HPMC), is a water-soluble polymer
commonly used as film-forming material. Within this study OTFs for furosemide (FUR) delivery
were produced by solvent casting technique, using hydroxypropyl methylcellulose (HPMC) as
matrix-forming. Data on solubility, oral absorption, and permeability classify FUR into Class IV
of the Biopharmaceutical Classification System [7,8].
In order to enable drug incorporation within HPMC films, a multifunctional excipient was
included in the formulation. Hydroxypropyl-beta-cyclodextrin (HP-β-CD) was used because it may
fulfill several different roles, i.e., it may increase the loading efficiency of the OTFs while avoiding
drug recrystallization [9], and it helps the taste-masking and improves drug absorption [10–12].
Work is mainly focused on the study, analysis, and modeling of the in vitro release of furosemide
from HPMC-based OTFs, with and without the inclusion of HP-β-CD.
Three different apparatuses, namely the Franz cell, the millifluidic flow-through device [13–15],
and the USP II paddle type dissolution apparatus, were used and the results compared.
Mathematical models capable of describing the release process from erodible OTFs in different
apparatuses have been developed. In particular we propose a new mathematical approach to describe
drug transport and release in a Franz cell, by removing a standard assumption, namely that of perfect
mixing in the accepting chamber.
2. Materials and Methods
2.1. Materials
Hypromellose 5 (HPMC5, 5 mPas at 1% w/w and 25 ◦C) and glycerol were obtained from NMD,
Oslo, Norway. Potassium phosphate monobasic (KH2PO4), sodium phosphate dibasic dihydrate
(Na2HPO4), potassium permanganate (KMnO4), and sodium chloride (NaCl) used for the preparation
of simulated saliva were purchased from Merck, Darmstadt, Germany. Methanol (MeOH) was from
VWR BHD Prolabo, Singapore. 2-Hydroxypropyl-β-cyclodextrins (HP-β-CD), Cavasol W7 HP Pharma,
degree of substitution 0.6–0.9 mol per anhydroglucose unit, Mw ' 1396 g/mol, was from ISP, Koln,
Germany. Furosemide and ethanol were purchased from Sigma Aldrich, Steinheim, Germany.
MQ water produced by dispenser Milli-Q Integral 3 Water Purification System, Merck Millipore,
Billerica, MA, USA, was used throughout the study. For the preparation of mobile phase were used
Methanol (MeOH, VWR BHD Prolabo, Singapore) and MQ water produced by dispenser Milli-Q
Integral 3 Water Purification System, Merck Milliepore, Billerica, MA, USA .
2.2. Film Production
Films were produced by a casting/solvent evaporation technique using HPMC5 (8% w/v), and the
plasticizer glycerol (2% w/v) with or without HP-β-CD (5% w/v).
Pharmaceutics 2018, 10, 222 3 of 24
HPMC5, Gly, and HP-β-CD were dissolved in 100 mL of 0.5 mg/mL furosemide solution in
simulated saliva (phosphate buffer, pH 6.7, containing NaCl). The resulting solution was maintained
under magnetic stirring for 5 h at room temperature and protected from light. The mixture was casted
onto a Coatmaster 510 ERICHSEN GmbH and CO. KG, Hemer, Germany, equipped with the Wasag
Model 288 Film Applicator System, with a gap opening of 1000 µm resulting in a wet film thickness of
1000 µm. The film was dried at room temperature for 15 h with the light switched off. The thin film
was detached from the coatmaster and stored in an aluminium sachet to protect it from light.
The obtained OTFs were characterized for thicknesses using Cocraft 2.5 micrometer (0–25 mm).
Uniformity of furosemide content was evaluated as follows. A large sample of OTF was cut into
smaller pieces (dimensions 3 cm × 1 cm) and, each of them, was solubilized in 10 mL of simulated
saliva (at room temperature) until complete dissolution. The solutions obtained were first diluted
with EtOH (1:20 v/v) to obtain the dissociation of the inclusion complex and then analyzed in UV/Vis
Spectrophotometer (UV-2401 PC Shimadzu Corporation, Kyoto, Japan) at λ = 276 nm.
2.3. Rheological Studies
Rheological experiments were carried out with a TA HR 2 stress-control Rotational Rheometer
operated by software TRIOS (TA instruments, Waters Spa, Milan, Italy). Flow curves of all the
film-forming solutions were obtained with a cone-plate geometry (diameter 40 mm, angle 1◦) in the
range of 0.01–1000 Pa at 25.0 ± 0.1 ◦C. All the experiments were carried out at least in triplicate.
2.4. Mechanical Strength Tests
Mechanical strength tests were carried out on square OTFs pieces (2 cm × 2 cm) with a Texture
Analyzer TA-XT plus (Stable Microsystems, Godalming, UK) using a cylindrical probe with a plane
flat-faced surface (radius 3.52 mm).
The sample was fixed in the sample holder, and the probe was moved down at a speed of
1.0 mm/s. The measurement started when the probe came in contact with the film sample (trigger
force 0.05 g). The probe moved at a constant test speed of 0.1 mm/s until the film ruptured, and
the applied force and displacement (penetration depth) was registered. The puncture strength and
elongation to break were calculated [16].
Puncture strength was calculated as
Puncture strength (N/mm2) = Puncture force (N)/Area of the probe (mm2)
where the Puncture force is the maximum force recorded in the test.
Elongation to break was calculated according to the following equation
Elongation to break =
(√
a′2 + b2 + r
a
−1
)
× 100 (1)
where a is the radius of the film in the sample holder opening, i.e., initial length, a′ is the initial length
minus radius of probe, b is the penetration depth/vertical displacement by the probe, and r is the
radius of the probe.
All measurements were conducted at room conditions and repeated for different pieces of each
formulation (n = 20).
2.5. Phase Solubility Study of Furosemide with HP-β-CD
Phase solubility studies were carried out according to the method reported by Higuchi and
Connors [17]. Excess amounts of furosemide were added to saliva simulata solutions (pH = 6.7)
containing HP-β-CD in different concentrations (0%, 2%, 4%, 6%, 8%, 10% w/v) and shaken for 3 days
at constant temperature (T = 37 ◦C) in a cabinet shaker. The filtered solutions were diluted with EtOH
(1:20 v/v) and analyzed on UV spectrophotometer at λ = 276 nm to define solubility characteristics.
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2.6. Swelling-Erosion Tests
A square piece (1 cm × 1 cm) of dry film was weighted (initial weight W0) and inserted in a dry
beaker (tare weight Wb). Then, 1.5 mL of simulated saliva (pH 6.7) at 37 ◦C ± 0.1 ◦C was added on
the film with a pipette to allow the film to swell and erode, taking great care not to wet the beaker.
At regular time instants t f , the excess of simulated saliva (not absorbed by the film) was carefully
removed with a syringe, the system made by wet film + beaker was weighed (thus recording the total
weight W(t f ) +Wb), and new fresh saliva was added to continue the test. From the difference between
the total weight of the system and the weight of the beaker Wb, we estimated the weight of the swelling
film at time t f . The weight of the film increases until dissolution occurs and the film weight starts to
decrease because the eroded material is removed together with the excess of simulated saliva.
2.7. Release Studies with Vertical Franz Diffusion Cell
Release studies were carried out at 37 ◦C using a jacketed Franz diffusion cell (PermeGear,
Hellertown, PA, USA).
The cylindrical donor compartment had a cross-section area of 1 cm2. The donor chamber was
separated from the receptor chamber by a dialysis membrane (Spectra/Porr 2, Standard RC Discs,
MWCO 12–14 kDa, Spectrumr Laboratories, Rancho Dominguez, CA, USA) having an area of 1 cm2
and thickness δm = 45 µm.
The receptor chamber was filled with 7.9 mL of sonicated simulated saliva pH 6.7 at 37 ◦C under
constant stirring (500 rpm).
Aliquots of 200 µL were withdrawn at fixed time intervals and replaced with equal volumes of
fresh saliva.
For blank experiments, the donor compartment was loaded with (1) 0.1 mL of furosemide solution
(0.18 mg/mL in simulated saliva) and (2) 0.1 mL of furosemide + HP-β-CD solution (0.18 mg/mL
of furosemide + 5% w/v of HP-β-CD in simulated saliva). Blank experiments were performed for
estimating the diffusion coefficient of furosemide D f0 and furosemide/HP-β-CD complex D
f+CD
0 in
the solvent solution and in the dialysis membrane.
Release studies in the Franz cell were also performed by placing 1 cm2 of thin dry film (with or
without HP-β-CD) in the donor compartment. The film, in contact with the solvent solution (simulated
saliva in the receptor chamber) through the dialysis membrane, swells and erodes, but the eroded
material is not washed away and removed but it remains in the donor compartment. The drug
(furosemide or furosemide/HP-β-CD complex) is therefore released from the donor chamber to the
receptor compartment. Release experiments from films in the Franz cell were performed to estimate
the effective diffusion coefficient of furosemide D fG and furosemide/HP-β-CD complex D
f+CD
G in the
swollen gel.
Furosemide was quantified by HPLC analysis carried out with a Shimadzu apparatus
(Kyoto, Japan) equipped with Pump LC-20AD, Auto injector SIL-9A, Detector SPD-10A, Plotter
Chromatopak C-R5A, Column oven IGLOO-CIL HPLC column thermostat, SPC GmbH, Separation
column, C18, 4 µm, 3.9 × 150 mm Cartridge Nova-Pakr Waters, USA with a Nova-Pakr Guard
Column C18, 4 µm, 3.9 × 20 mm.
The HPLC analysis was carried out using a mixture of MeOH and phosphate buffer (pH 6.8)
(30:70, v:v) as the mobile phase, with a flow rate 1 mL/min and monitoring furosemide at λ = 276 nm.
2.8. Release Studies with Paddle Type Dissolution Apparatus (USP II)
A rotating paddle apparatus (USP II Prolabo Dissolution Tester, Sion, France) was used to test
the release at 37 ◦C and 50 rpm. OTFs were anchored with a wire mesh to the bottom of the vessel
filled with 500 mL of preheated simulated saliva (pH 6.7). In this way, both film surfaces were
exposed to the solvent. Aliquots (2 mL) of the release medium were withdrawn at fixed time intervals
and replaced with equal volumes of fresh saliva. The solutions obtained were analyzed in UV/Vis
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Spectrophotometer (UV-2401 PC Shimadzu Corporation, Kyoto, Japan) at λ=276 nm. Tests were
repeated in triplicate.
2.9. Release Studies with Millifluidic Flow-through Device (MFTD)
Drug release studies from thin films were also performed using the recently proposed millifluidic
continuous flow-through device (henceforth referred to with the acronym MFTD) [14,15].
A schematic representation of the device and of the experimental set up are shown in Figure 1.
The device is called “millifluidic” because it has a characteristic operative volume in the order
of mm3. The millifluidic device has been designed to mimic mouth physiological conditions because
of the laminar tangential solvent flow, the flow rates comparable to salivary flow rates and low
hold-up volume.
In the MFTD, thin film strips were placed on the bottom plate of a dissolution cell with dimensions
of 2 × 9 × 30 mm. These dimensions were chosen to assure a regular flow through the device also
after complete film swelling. The surface area of the OTF exposed to the solvent tangential laminar
flow was 9 × 30 mm.
One side of the film was exposed to the tangential solvent flow, the other side in contact with the
bottom wall of the dissolution cell. As soon as wetted, strips adhered firmly to the plate, and there was
no need to make use of a double-sided tape, thus avoiding unpredictable and ruinous detachments or
floating problems often encountered with other existing devices (USP I, USP II).
Dissolution medium (simulated saliva) was kept in a reservoir at 37± 1 ◦C and circulated through
the dissolution cell in open loop, by means of a volumetric pump (see Figure 1). Flow rates investigated
in this work were in the range Q ∈ [1–5] mL/min corresponding to laminar flow conditions with
Reynolds numbers Re = ρ < v > de/µ ∈ [1–20], de being the hydraulic radius de = 4 × cross-section
area/wetted perimeter = 3.27 mm. Flow rates investigated were comparable with salivary flow rates
Q ∈ [1–4] mL/min.
Solution coming out the cell was sent to the UV/Vis analyzer (UV-2401 PC, Shimadzu Corporation,
Kyoto, Japan, continuous flow cell, optical path 1 mm) in order to quantify the amount of active
ingredient released from the swelling film. Drug concentration values cs(t) mg/mL were recorded
every 2 s. The amount of drug released was calculated with a calibration curve. Calibration curve
for furosemide reference standard (RS) was obtained by measuring the UV absorption (λ = 276 nm)
in dissolution medium (simulated saliva). The linearity of the calibration curves was confirmed in
the range 1–100 µg/mL with a regression coefficient (R2) value of 0.999. Limits of detection and
quantification are 0.2 µg/mL. Tests were repeated in triplicate.
The differential F(t) and integral Mt release curves were subsequently computed from the
experimental data as follows
F(t) = Q cs(t) , Mt =
∫ t
0
Qcs(t′)dt′ =
∫ t
0
F(t′)dt′ (2)
t f being a final time for the experimental test sufficiently long to ensure the complete drug release.
The final time t f was changed according to the flow rate Q. The smaller the flow rate Q, the longer the
time interval required for complete drug release.
solvent flowing
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Figure 1. Millifluidic flow-through device. Schematic representation of the experimental set-up.
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3. Transport Models
In this section, we present all the mathematical models we adopted for the analysis of experimental
data of swelling-erosion tests, and the drug release in the Franz cell, in the millifluidic flow-through
device and in the USP II apparatus.
3.1. Swelling-Erosion Modeling of Thin Films
We adopted a 1D model of swelling and erosion of thin films. Swelling along the z direction
(orthogonal to the x− y plane representing the flat surface of the OTF) is a moving boundary problem.
The solvent mass balance equation, written in terms of the solvent, volumetric fraction φ reads
as [13,15,18,19]
∂φ
∂t
=
∂
∂z
(
Ds(φ)(1− φ)∂φ
∂z
)
, R(t) < z < S(t), t > 0 (3)
where S(t) and R(t) are, respectively, the position of the erosion front (gel–solvent interface) and
swelling front (glassy–rubbery interface) at time t coming out the cell. Ds(φ) is the solvent diffusion
coefficient, modeled as an increasing function of the solvent volumetric fraction φ
Ds(φ) = DsG exp
[
−βs
(
φ− φeq
φ0 − φeq
)]
, βs ≥ 0 (4)
where DsG is the solvent diffusion coefficient in the fully swollen gel, φeq and φ0 are the solvent
volumetric fraction at equilibrium and in the dry film, respectively. If βs = 0, then the solvent diffusion
coefficient Ds is assumed constant and equal to DsG.
On the glassy-rubbery front R(t), a threshold concentration to initiate swelling φg > φ0 is
assumed [20] and the front movement is given by the Stefan condition
φ = φg, (φg − φ0)dRdt = −D
s(φg)(1− φg) ∂φ
∂z
∣∣∣∣
R(t)
at z = R(t). (5)
When R(t) reaches z = 0, the glassy phase disappears and the no-flux boundary condition applies
∂φ
∂z
= 0 at z = 0. (6)
On the gel-solvent interface S(t), thermodynamic equilibrium φeq is assumed and the front
movement is described by the Stefan condition
φ = φeq,
dS
dt
= DsG
∂φ
∂z
∣∣∣∣
S(t)
− Rdis at z = S(t) (7)
where Rdis is the disentanglement rate accounting for erosion [18,19,21–24]
Rdis = C (1− φ)1.625 (8)
where C [µm/s] is a constant depending on the fluid-dynamic conditions.
The no-flux boundary condition at z = 0, Equation (6), represents a symmetry boundary
condition when both film surfaces are exposed to the solvent like in a swelling test or in a release
experiment in USP apparatuses. Correspondingly, the moving boundary problem has to be solved
with initial conditions
R(0) = S(0) = L0/2 , φ(z, 0) = φ0 , 0 ≤ z ≤ L0/2 (9)
where L0/2 is the half thickness of the dry film.
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If film swelling occurs in the millifluidic device, Equation (6) represents an impermeability
condition since the thin film adheres firmly on the bottom wall of the device and no solvent permeation
is allowed at the bottom surface of the film. Therefore, the moving boundary model describing film
swelling and erosion in the MFTD must be solved with initial conditions
R(0) = S(0) = L0 , φ(z, 0) = φ0 , 0 ≤ z ≤ L0 (10)
where L0 is the initial thickness of the dry film.
The swelling-erosion model presented is a nonlinear moving boundary model that must be
necessarily numerically solved and therefore no explicit equations for the time evolution of the
glassy-rubbery interface R(t) or for the rubbery-solvent interface S(t) are available. When modeling
drug release in different devices (USP II apparatus and MFTD), the drug transport equations must be
solved together with the moving-boundary model equations describing the swelling-erosion dynamics,
that furnish, at each time instant, front positions R(t) and S(t).
3.2. Drug Release Modeling in a Vertical Franz Diffusion Cell
Drug release data obtained with a vertical Franz diffusion cell can be analyzed by adopting
different transport models with increasing complexity.
Model I. The simplest model assumes that the drug is uniformly distributed in both the donor
chamber (volume Vd, concentration cd(t)) and in the accepting compartment (volume Vres perfectly
mixed, concentration cres(t)). Donor and accepting chambers are separated by a membrane with area A
and thickness δm. Therefore, the macroscopic balance equation of drug in the donor chamber reads as
Vd
dcd
dt
= −D
d
m
δm
A (cd − cres) , cd(0) = c0 (11)
where c0 is the initial drug concentration in the donor compartment, and Ddm is the drug diffusivity in
the membrane, which can be assumed equal or lower than drug diffusivity Dd0 in the solvent solution
loaded in the receptor chamber. This intrinsically depends on the drug molecular weight and the
membrane cutoff.
By assuming perfect sink conditions cres(t) = 0, the amount of drug released up to time t attains
the form
Mt = Vdc0 −Vdcd(t) = M0
(
1− exp
(
−D
d
m A
δmVd
t
))
. (12)
This model neglects drug concentration gradients in the donor compartment and is
extremely unreliable.
Model II. A more accurate model accounts for drug concentration gradients along the vertical
direction z in both the donor chamber −δd ≤ z ≤ 0 and in the membrane 0 ≤ z ≤ δm. The membrane
is placed at z = 0, the z axis is oriented towards the bottom, and δd is the thickness of the solvent
solution placed in the donor compartment.
By adopting a purely diffusive transport equation for drug concentration cd(z, t), the model
equations read as
∂cd
∂t
= Dd
∂2cd
∂z2
, cd(z, 0) = c0 , −δd < z < 0 (13)
∂cd
∂t
= Ddm
∂2cd
∂z2
, cd(z, 0) = 0 , 0 < z < δm (14)
∂cd
∂z
∣∣∣∣
x=−δh
= 0 , Dd
∂cd
∂z
∣∣∣∣
z=0−
= Ddm
∂cd
∂z
∣∣∣∣
z=0+
, cd(δm, t) = cres(t) (15)
where Dd is the drug diffusivity in the solution placed in the donor compartment.
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At this point, we can distinguish between three different levels of model accuracy.
Model IIa. By assuming perfect sink conditions, model Equations (13)–(15) can be solved with
the further condition cres(t) = 0, and Mt can be evaluated, at each time instant t, as
Mt = M0 − A
∫ δm
−δh
cd(z′, t)dz′. (16)
Model IIb. By accounting for the finite volume Vres of the accepting chamber, the concentration
cres(t), still assumed uniform in the accepting chamber, evolves in time according to the macroscopic
balance equation
Vres
dcres
dt
= −Ddm A
∂cd
∂z
∣∣∣∣
z=δm
, cres(0) = 0 (17)
that must be solved together with the transport Equations (13)–(15). Correspondingly, the amount of
drug released up to time t can be computed from Equation (16) or equivalently as
Mt = Vres cres(t). (18)
Model IIc. It should be observed that, during the experiment, one performs withdrawals
(volume Vp at specific time instants ti) from the accepting chamber, and this influences the diffusion
process, since each withdrawal reduces almost instantaneously the concentration cres of a quantity
∆cres = cres(1−Vp/Vres). The withdrawal does not alter Vres if an equal volume Vp of solvent is
replaced just after the withdrawal.
The assumption of perfect mixing in the accepting chamber implies cp(ti) = cres(ti) and the effect
of withdrawals can be accounted for in the balance equation for cres as follows:
Vres
dcres(t)
dt
= −Dm A ∂cd
∂z
∣∣∣∣
z=δm
−
Ni(t)
∑
j=1
Vp cp(tj) (19)
where Ni(t) is the number of withdrawals performed from t = 0 up to time t.
By solving the transport Equations (13)–(15) together with Equation (19), Mt can be evaluated as
Mt = Vres cres +
Ni
∑
j=1
Vpcp(tj). (20)
By focusing on Equation (20), one can observe that it represents the usual way the experimental
integral release curve is evaluated from the experimental differential release curve (represented by
withdrawal concentrations cp(ti) at withdrawal time instants ti)
Mst (ti) = Vrescp(ti) +
Ni(ti)
∑
j=1
Vpcp(tj) (21)
if one assumes perfect mixing in the donor chamber so that cres(ti) = cp(ti).
Therefore, experimental integral release curves—as usually reported in the whole literature—are
intrinsically based on the assumption that the acceptor chamber is perfectly mixed and that
the withdrawal concentration cp(ti) is representative of the (uniform) concentration cres(t) at the
withdrawal time instant ti.
Model III. In order to verify the validity of the hypothesis of perfect mixing, we performed
a release experiment in an unjacketed Franz cell with a colored marker and investigated, by visual
inspection, the actual mixing in the receptor chamber during the release process.
We choose to adopt an unjacketed Franz cell (with dimensions very close to the jacketed Franz
cell adopted for furosemide release experiments) in order to have a better visualization of the
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mixing/diffusion process occurring within the receptor chamber and to identify which portion of it is
actually “well mixed”. Experiments are performed at laboratory temperature T ' 25 ◦C with KMnO4
0.1 M in distilled water.
We investigated two different rotational speeds, namely 100 (Figure 2) and 500 rpm (Figure 3).
Rotational speeds of 100–200 rpm are usually adopted because they do not create problems due
to the formation of micro bubbles that can float, rise, and stratify close to the dialysis membrane.
The rotational speed of 500 rpm is extremely high. It guarantees a very good mixing (at least in the
cylindrical part of the receiving compartment) but requires a preliminary sonication of the solvent
solution (simulated saliva) in order to minimize bubble formation.
From Figures 2 and 3, it can be clearly observed that the lateral arm is almost unaffected by
mixing induced by the magnetic stirrer. In fact, the dye concentration in the lateral arm is negligible
or at least significantly lower than that in the main stirred body of the receptor chamber for both
rotational speeds. Moreover, it can be clearly identified a “color/concentration transition zone” at the
connection between the main cylindrical body (well mixed, especially at 500 rpm) and the later arm
(totally unmixed).
Figure 2. Release experiment in an unjacketed Franz cell at T = 25 ◦C with a colored marker (KMnO4
0.1 M in distilled water). Rotational speed: 100 rpm.
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Figure 3. Release experiment in an unjacketed Franz cell at T = 25 ◦C with a colored marker (KMnO4
0.1 M in distilled water). Rotational speed: 500 rpm. The reason why the color is much fader in this
experiment as compared to that with 100 rpm—the concentration of KMnO4 being the same—is only
a matter of colors in the photo (different camera and different light exposition).
For this reason, we were forced to abandon the simplifying hypothesis of perfect mixing of the
accepting chamber and to distinguish within it three different domains (see Figure 4) characterized by
different fluid dynamic regimes.
Domain 1. A cylindrical body (Domain A, volume Vcil ' 7.1 mL), in the bottom of which is placed the
magnetic stirrer, that we reasonably can assume perfectly mixed (especially for high rotation speeds)
or equivalently characterized by an extremely high drug diffusion coefficient Ddcil = (10
5 ÷ 107)Dd0 ,
Dd0 being the drug diffusivity in the unstirred solvent solution.
Domain 2. A lateral arm (Domain C, volume Varm ' 0.5–0.6 mL) that is not reached by vortices
generated by the magnetic stirrer and in which we assume a purely diffusive drug transport mechanism
with diffusivity Dd0 .
Domain 3. A third domain similar to a truncated cone (Domain B, volume Vtc ' 0.2–0.3 mL),
connecting the cylindrical body to the lateral arm, where the syringe carries out withdrawals and
solvent reintegrations. In this connection domain, we can assume that the drug diffusion coefficient is
position-dependent.
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Figure 4. Schematic representation of different domains in a Franz cell. Donor compartment, drug
diffusivity Dd. (A) Cylindrical body, perfectly mixed, drug diffusivity Ddcil = (10
5 ÷ 107) × Dd0 .
(B) Truncated cone region, drug diffusivity Ddtc(s), Equation (22). (C) Lateral arm, drug diffusivity D
d
0 .
If we introduce a curvilinear abscissa s (see Figure 4), we can assume that the drug diffusion
coefficient exponentially decreases from Dd = Ddcil for s = 0, i.e., in contact with the well mixed
cylindrical body, to Dd = Dd0 when the drug enters the lateral arm
Ddtc(s) = D
d
0 + (D
d
cil − Dd0) exp (−βDs) with βD ' 500 m−1. (22)
Equation (22) permits us to model drug transport in Domains B and C (total volume
Vtc +Varm ' 0.8 mL) as a pure diffusive process with a space-dependent diffusion coefficient.
The model we implemented thus describes drug release in a Franz cell with
1. a purely diffusive transport equation in the donor compartment with drug diffusivity Dd,
2. a purely diffusive transport equation in the membrane with drug diffusivity Ddm ≤ Dd0 ,
3. a purely diffusive transport equation in the cylindrical body (Domain A) with drug diffusivity
Ddcil >> D
d
0 ,
4. a purely diffusive transport equation in the truncated cone region (Domain B) with diffusivity
Ddtc(s), Equation (22), and
5. a pure diffusive transport equation in the lateral arm (Domain C) with drug diffusivity Dd0 in
a quiescent solvent solution.
Continuity of drug concentration and diffusive fluxes are enforced at all internal boundaries
(boundaries between two distinct domains) and zero flux boundary condition at the top of the
donor compartment and at the exit of the lateral arm are assumed from the assumption of negligible
solvent evaporation.
The split of the accepting chamber into three distinct domains led us to a more accurate evaluation
of the withdrawal concentration cp(ti) as the average drug concentration ctc in the truncated cone
(Domain B) at time ti
cp(ti) = ctc =
1
Vtc
∫
Vtc
cd(x, ti)dx . (23)
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For the sake of simplicity, we assume that the volume of truncated cone domain Vtc equals the
withdrawal volume Vp. In this way, the influence of the withdrawal and subsequent reintegration of
solvent solution can be simply modeled as an instantaneous complete depletion of drug concentration
in the truncated cone (Domain B) at the withdrawal time instants ti.
A correct estimate of the drug diffusion coefficient in the donor compartment D can therefore be
obtained by a direct comparison between experimental data of withdrawal concentrations cp(ti) and
model predictions (Equation (23)).
In point of fact, the integral release curve accounting for non-perfect mixing
Mt =
∫
Vcil
cd(x, ti)dx +
∫
Vtc
cd(x, ti)dx +
∫
Varm
cd(x, ti)dx +
Ni
∑
j=1
Vpcp(tj)
= Vcilccil +Vtcctc +Varmcarm +
Ni
∑
j=1
Vpctc(tj) (24)
will necessarily differ from the “experimental” integral release curve Equation (21) based on the
assumption of perfect mixing, i.e., ccil = ctc = carm = cres. In particular, the integral release curve Mst
based on perfect mixing assumption tends to underestimate Mt since ctc < ccil .
3.3. Drug Release Modeling in the MFTD
The drug release process from the OTFs in the millifluidic device is described with a 2D model.
Let x be the axial flow direction, spanning the channel length 0 ≤ x ≤ Lx, Lx = 30 mm. Let z be
the vertical direction (preferential swelling direction) 0 ≤ z ≤ Lz, Lz being the channel thickness
Lz = 2 mm. Let Ly be the channel width Ly = 0.9 mm. The thin film exposed to the solvent tangential
flow is a thin strip of surface Lx × Ly and initial thickness L0 << Lz.
Let cG(x, z, t) and cF(x, z, t) be the drug concentration in the swelling film and in the flow channel,
respectively.
Swelling-erosion dynamics is described by the 1D model presented in Section 3.1 and evolves
independently of the drug release process. The swelling model furnishes, at each time instant t,
the gel–solvent S(t), and the glassy-rubbery R(t) front positions.
Drug balance equation in the gel layer reads as
∂cG
∂t
= DdG∇2cG, 0 < x < Lx, R(t) < z < S(t) (25)
where DdG is the effective drug diffusivity in the swollen gel.
Equation (25) must be solved with the boundary condition of impermeable wall at x = 0, Lx and
Stefan condition at glassy-rubbery interface z = R(t):
dR(t)
dt
(c0 − cG)
∣∣∣∣
x,R(t)
= DdG
∂cG
∂z
∣∣∣∣
x,R(t)
(26)
where c0 is the initial drug loading in the dry film. When R(t) reaches z = 0, then dR/dt = 0 and
consequently Equation (26) transforms into the impermeability condition at the bottom wall z = 0 of
the device. Initial conditions are
cG(x, z, 0) = c0 for 0 ≤ z ≤ L0, ∀x, S(0) = R(0) = L0. (27)
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The drug balance equation in the solvent (flowing in laminar flow conditions) is
a convection–diffusion transport equation
∂cF
∂t
= Dd0∇2cF − vx(z, t)
∂cF
∂x
, 0 < x < Lx, S(t) < z < Lz (28)
where Dd0 is the drug diffusivity in the solvent solution, and vx(z, t) is the velocity of the solvent in
the channel:
vx(z, t) =
6Q(z− S(t))(Lz − z)
Ly(Lz − S(t))3 ,
∫ Lz
S(t)
vx(z′, t)dz′ =
Q
Ly
(29)
where the parabolic axial velocity field vx(z, t) is evaluated from lubrication theory by enforcing
a constant flow rate and no slip boundary conditions and evolves in time according with the gel–solvent
interface dynamics.
Equation (28) has to be solved with initial conditions
cF(x, z, 0) = 0 for S(0) ≤ z ≤ Lx, ∀x, S(0) = R(0) = L0 (30)
and boundary conditions representing Danckwertz conditions at the channel outlet and no flux
condition at the top impermeable channel wall
cF|0,z = 0 , ∂c
F
∂x
∣∣∣∣
Lx ,z
= 0 ,
∂cF
∂z
∣∣∣∣
x,Lz
= 0. (31)
The drug concentration profiles in the channel and in the swollen gel are connected by the
continuity condition at the gel-solvent interface S(t):
cF
∣∣
x,S(t) = c
G∣∣
x,S(t), D
d
0
∂cF
∂z
∣∣∣∣
x,S(t)
= DdG
∂cG
∂z
∣∣∣∣
x,S(t)
. (32)
Model results and experimental data can be compared in terms of differential release curves F(t)
vs. t and integral release curves Mt vs. t by computing
F(t) = Ly
∫ Lz
S(t)
vx(z′, t)cF(Lx, z′, t)dz′ , Mt =
∫ t
0
F(t′)dt′. (33)
3.4. Drug Release Modeling in the USP II Apparatus
The drug release process from the OTFs in the USP II apparatus can be simply modeled by a 1D
diffusive transport equation describing drug transport in the swelling film along the preferential
swelling direction z (orthogonal to the flat surface of the thin film)
∂cG
∂t
= DdG
∂2cG
∂z2
, R(t) < z < S(t) (34)
to be solved with the equations describing the swelling-erosion dynamics (presented in Section 3.1)
that furnishes, at each time instant, the gel-solvent S(t) and the glassy-rubbery R(t) front positions.
Equation (34) must be solved with the Stefan condition at the glassy-rubbery interface z = R(t):
dR(t)
dt
(c0 − cG)
∣∣∣∣
R(t)
= DdG
∂cG
∂z
∣∣∣∣
R(t)
. (35)
When R(t) reaches z = 0, then dR/dt = 0 and consequently Equation (35) transforms into the
symmetry condition at z = 0, since both surfaces of the thin film are exposed to the solvent solution
and the initial condition is therefore S(0) = R(0) = L0/2, L0/2 being the half thickness of the dry film.
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In this device, given the large volume of solvent solution (500 mL) and the good mixing induced
by paddle rotation, we can reasonably assume a perfect sink condition, thus enforcing at each time
instant cG = 0 at z = S(t).
The total amount of drug released up to time t can be evaluated as
Mt = A
(
c0L0 − 2
∫ S(t)
R(t)
cG(z′, t)dz′
)
(36)
A being the thin dry film surface area.
4. Results and Discussion
4.1. Film Thickness, Drug Loading, and Moisture Content
Thicknesses of OTFs were in the range 70–95 µm for OTFs without HP-β-CD and 110–140 µm for
OTFs with HP-β-CD.
The furosemide content in dry films (with and without HP-β-CD) was 61± 8 µg/cm2 of film.
The residual water weight fraction (with and without HP-β-CD) was about 12–14% w/w.
4.2. Analysis of Rheological Studies and Mechanical Strength Tests
HPMC OTFs were produced by the solvent casting technique which involves the initial deposition
and successive spreading of the polymeric solution on a solid support. The quality and properties of
the final product are critically dependent on the viscosity of the starting polymeric solution.
If the viscosity is too low, the formulation will flow off the glass plate of the Coatmaster, whereas,
if the viscosity is too high, the spreading with the knife will be problematic and the air bubbles will
not be removed and leaves structures or holes in the dry film. The viscosity of 8% w/v HPMC was
preliminary selected based on trial and errors and was found to be ideal for the preparation of thin
films with the Coatmaster instrument.
It was important to perform rheological studies in order to evaluate the effect of glycerol and,
above all, of HP-β-CD on the viscosity of the film-forming solutions [25].
The flow curves (Figure S1) show the same pseudoplastic behavior and almost the same viscosity
for HPMC alone and for HPMC with glycerol and HP-β-CD. Therefore, the polymeric solution resulted
rheologically stable and its viscosity substantially unaffected by the inclusion of glycerol and HP-β-CD.
Similar results were observed for the corresponding dried films which show comparable resistance
and elasticity also in the presence of high amount of HP-β-CD (Figure S2).
4.3. Analysis of Phase Solubility of Furosemide with HP-β-CD
The phase solubility plot, i.e., furosemide concentration at saturation c f [mol/L] vs. cyclodextrin
concentration cCD [mol/L], is shown in Figure 5. It shows an AL type solubility curve [17].
The linear behavior
c f = α+ β cCD , α = 0.0057 (mol/L) , β = 0.0183 (ad) (37)
characterized by a slope β significantly lower than unity indicates the formation of a 1:1 complex
furosemide/HP-β-CD.
According to this hypothesis, a complexation equilibrium constant K1:1
K1:1 =
β
α(1− β) = 3.27 [(mol/L)
−1] (38)
has been estimated as in Brewster and Loftsson [26]. Therefore, we can assume that, in the
presence of an excess of HP-β-CD, all the furosemide appears to be complexed in a 1:1 furosemide/
HP-β-CD complex.
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Figure 5. Phase solubility diagram of furosemide with HP-β-CD in simulated saliva (pH = 6.7) at
T = 37 ◦C.
4.4. Analysis of Swelling-Erosion Tests
Figure 6A shows the results of swelling tests for both films, with and without HP-β-CD. W(t)/W0
represents film weight at time t rescaled onto the initial weight of the dry film.
We observe that both films start to swell, reach a maximum weight (approximately 3.5 times the
initial one), and then begin to dissolve. Dissolution is very fast and almost complete in 4 min for film
without HP-β-CD and in 3 min for film including HP-β-CD.
By adopting the swelling-erosion model presented in Section 3.1, we can estimate the solvent
diffusion coefficient DsG and the erosion constant C. Model parameters φ0, φg, and φeq adopted for
both films are reported in Table 1 together with best fit parameters DsG and C.
In particular, φ0 is estimated from residual water weight fraction 12–14% w/w in the dry film as
obtained from uniformity of content data. The glassy-rubbery threshold φg is assumed to be 10–15%
greater than φ0, and φeq has been estimated from experimental data in order to obtain a maximum
swelling Wmax/W0 ' 3.5.
The best fit value of the solvent diffusion coefficient DsG = 7.9× 10−9 m2/s is in perfect agreement
with the corresponding value obtained for simulated saliva in film made of pure HPMC K15M,
as reported in [15]. In [15], no plasticizer was added, and the erosion effect was negligible. In the
present case, the presence of glycerol as plasticizer may be responsible, together with a different
viscosity grade between HPMC5 (used in the present paper) and HPMC K15M, of the significant
erosion effect observed.
Figure 6B shows the comparison between experimental data and model predictions (continuous
lines) in terms of the dimensionless time τ = tDsG/L
2
0, i.e., the physical time rescaled onto the
diffusion time that takes into account film thickness (significantly larger for films with HP-β-CD).
This representation better highlights that the erosion effect is larger for films with HP-β-CD,
as confirmed from best fit values for the erosion constant C for film with and without HP-β-CD.
It should be noticed that swelling-erosion data have been mainly used in order to estimate
φeq and DsG and not the disentanglement rate Rdis, because Rdis from these experiments is largely
overestimated. In fact, when the film swells and begins to dissolve, it splits into smaller pieces that can
be removed from the beaker when the excess of simulated saliva is removed. This is evident if one
compares the time scales for complete dissolution (3–4 min) in the swelling-erosion test and the time
scale for complete drug release in USP II and in MFTD (10–20 min, depending on the fluid dynamic
conditions). Therefore, a more accurate estimate of the disentanglement rate Rdis can be obtained
by a correct modelization of drug release experiments that are strongly influenced by erosion effects
(see Section 4.6).
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From the maximum swelling Wmax/W0, we can estimate the thickness of swollen films when
inserted in the donor compartment of the Franz cell (see Section 4.5.2).
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Figure 6. Swelling-erosion tests. (A) Experimental data W(t)/W0 vs. t (min). (B) Experimental data
and model predictions W(τ)/W0 vs. the dimensionless time τ. The maximum swelling degree is
Wmax/W0 ' 3.5 with and without HP-β-CD.
Table 1. Parameters entering the swelling-erosion model.
Film L0 (µm) φ0 φg φeq DsG (m
2/s) C (µm/s) Rdis (µm/s)
without HP-β-CD 87 ± 5 0.21 0.3 0.89 7.95× 10−9 67.72 1.87
with HP-β-CD 126 ± 5 0.12 0.18 0.85 7.95× 10−9 84.37 3.86
4.5. Analysis of Release Kinetics in Franz Cell
4.5.1. Analysis of Blank Solutions
We preliminary analyze release data from blank solutions. The donor compartment was loaded
with 0.1 mL of furosemide solution 0.18 mg/mL or 0.18 mg/mL furosemide +5% w/v HP-β-CD.
Therefore, δd = 1 mm, M0 = 18 µg.
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Diffusivity of furosemide in the solvent solution D f0 is preliminary estimated from
Wilke–Chang’s relation
DWC[
cm2
s
] = 7.4× 10−8
√
ΨB MWBT)
ηBV0.6LB
(39)
where B indicates the solvent (water, ΨB = 2.26), and VLB = 317.6 is the LeBas drug molar volume of
furosemide obtained from a group contribution approach, considering the contributions of individual
atoms, functional groups, and cycles composing each molecule [27].
Figure 7 shows the experimental differential release curve (withdrawal concentrations cp(ti) at
different time instants) and the two models adopted: the perfect mixing Model IIc and the imperfect
mixing Model III with Dd = Dd0 = D
f
0 = 5.78× 10−10 m2/s and Ddm = 0.5Dd0 . It can be observed that
the imperfect mixing model is capable to accurately predict the differential release curve, while the
perfect mixing model (including the effect of withdrawals) significantly overestimate the withdrawal
concentrations.
This preliminary observation supports our initial hypothesis that only the imperfect mixing
model, when applied directly to differential release curve (and not to the integral release curve) led to
a correct estimate of drug diffusivity values.
 0
 0.5
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Figure 7. Differential release profile of furosemide blank solution. Filled circles represent experimental
withdrawal concentrations cp(ti). Continuous black line represents perfect mixing model predictions
(Model IIc). The red line with square points represent the imperfect mixing model predictions
(Model III).
The imperfect mixing model is therefore applied to differential release data of 0.1 mL of furosemide
solution 0.18 mg/mL furosemide +5% w/v HP-β-CD thus obtaining the following estimate for
the diffusivity of the furosemide/HP-β-CD complex D f+CD0 = 1.73 × 10−10 m2/s as obtained
from the best fitting of data reported in Figure 8A with D f+CDm = 0.25D
f+CD
0 . The diffusivity of
furosemide/HP-β-CD complex in the membrane has been assumed to be four times smaller than
the diffusivity in the solvent solution given the large dimension of the complex and the membrane
cutoff. The resulting diffusivity of furosemide/HP-β-CD complex D f+CD0 is significantly smaller than
furosemide diffusivity D f0 . A review of diffusivity values is reported in Table 2.
Figure 8B shows the integral release curves Mst (dashed curves with point) as usually evaluated
in the literature, i.e., from experimental data cp(ti) and Equation (21), by assuming a perfectly
mixed accepting compartment Vres = 7.9 mL. It can be observed that the integral release curve
Mst significantly underestimates the total amount of drug asymptotically released, i.e., M
s
t (∞) < M0,
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while the imperfect mixing model (continuous lines) predicts Mt(∞) ' M0. The two integral curves
Mt and Mst cannot coincide because they are based on different basic assumptions.
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Figure 8. Differential (A) and integral release curves (B) for blank solution of furosemide with
and without HP-β-CD. Continuous lines represent the imperfect mixing Model III predictions with
δd = 1 mm, δm = 45 µm, D
f
0 = 5.78× 10−10 m2/s, D
f
m = 0.5D
f
0 , D
f+CD
0 = 1.73× 10−10 m2/s and
D f+CDm = 0.25D
f+CD
0 . (A) Differential release curves cp(ti). (B) Integral release curves. M
s
t dashed
curves with points represent the integral release curves as evaluated from experimental data and
Equation (20) by assuming a perfectly mixed accepting compartment Vres = 7.9 mL. Continuous lines
represent the integral release curves as evaluated from the imperfect mixing Model III. Horizontal
dot-dashed line represent the amount of drug M0 initially loaded in the donor compartment.
Table 2. Diffusivity values (m2/s) estimated from release data in Franz cell.
D f0 D
f
m = 0.5D
f
0 D
f+CD
0 D
f+CD
m = 0.25D
f+CD
0 D
f
G D
f+CD
G
5.78× 10−10 2.89× 10−10 1.73× 10−10 4.32× 10−11 6.5× 10−11 5.4× 10−11
4.5.2. Analysis of Release Data from Films
When the thin dry film is placed in the donor compartment of the Franz cell, it comes in contact
with the solvent solution through the membrane and therefore swells and erodes. However, the eroded
material is not washed away and removed, but it remains in the donor compartment. Therefore,
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we assume that the swollen film thickness Th is the thickness attained when the maximum swelling
degree is reached, i.e.,
Th = Thdried− f ilm + Thwater−uptake = Thdried− f ilm +
(
Wmax
W0
)
W0
ρs A
(40)
where Wmax/W0 ' 3.5, ρs is the solvent density and A is the cross-section area of the donor
compartment. The resulting values are Th ' 450 µm for films without HP-β-CD and Th ' 580 µm for
films with HP-β-CD.
Given that the time scales of swelling are extremely small (order of 1 min), we can assume that
the film in a release experiment in the Franz cell is fully swollen since from the first time instants.
From the release curves of furosemide loaded in thin films (with and without HP-β-CD) and
placed in the donor compartment of a Franz cell, we can estimate the effective diffusivity of furosemide
D fG and of furosemide/HP-β-CD complex D
f+CD
G in the swollen gel.
The imperfect mixing model is therefore applied to differential release data of furosemide from
thin films in Franz-cell with δd = Th. Figure 9 shows the comparison between experimental differential
data cp(ti) for films with and without HP-β-CD and the model predictions with a best fit value of
effective diffusivity of furosemide in the swollen gel D fG = 6.5× 10−11 m2/s and a best fit value
of effective diffusivity of furosemide/HP-β-CD complex D f+CDG = 5.4× 10−11 m2/s. The effective
diffusivities in the swollen gel are very close for both furosemide and furosemide/HP-β-CD complex,
D fG ' 1.2× D
f+CD
G and significantly smaller than diffusivities in the solvent solution D
f
0 and D
f+CD
0 .
Diffusivities in the membrane are the same as obtained from blank data, i.e., D fm = 0.5D
f
0 for film
without HP-β-CD and D f+CDm = 0.25D
f+CD
0 . A review of diffusivity values is reported in Table 2.
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Figure 9. Rescaled differential release curves cp(t)/cp (24 h) vs. t [h] for films in the Franz cell.
Continuous lines (with small dots) represent imperfect mixing model III predictions with δm = 45 µm,
δd = 450 µm for films without HP-β-CD, and δd = 580 µm for films with HP-β-CD. Diffusivity values
D fG, D
f+CD
G , D
f
m, and D
f+CD
m are reported in Table 2.
Estimated diffusivities are directly used in the transport models for drug release in the MFTD and
in the USP II apparatus.
It must be observed that release experiments from erodible films in the Franz cell cannot be used
to estimate the actual release time scales in USP II or MFTD, because drug release in a Franz cell
is unaffected by erosion (the eroded material remains in the donor compartment). For this reason,
we observe that an almost complete release requires 10 h in the Franz cell and 10–15 min in USP II
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or MFTD (see Figure 10 in Section 4.6). Release data in the Franz cell have been exclusively used to
estimate the drug effective diffusivities in the swollen gel.
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Figure 10. Drug releases at 37 ◦C from USP II apparatus (paddle, 50 rpm) and from MFTD for different
flow rates Q = 1, 2, 4, 5 mL/min. (A) Mt vs. t, films without HP-β-CD. (B) Mτ vs. τ = tDsG/L
2
0, films
without HP-β-CD. (C) Mτ vs. τ, films with HP-β-CD. Arrows indicate increasing values of Q.
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4.6. Analysis of Release Kinetics in USP II and MFTD Apparatuses
In a recent work [14], drug release tests of commercially available melatonin strips obtained with
the flow-through device were compared with those obtained using the official USP XXXVII basket
(USP I) and paddle (USP II) apparatuses. The authors observed that, for flow rates comparable to
salivary flow rates (Q = 2–4 mL/min), the MFTD shows much slower release profiles by approximately
10–15 min of delay with respect to the other two investigated methods. Additionally, in the present
case, we observe that the official method (USP II) seems to significantly overestimate the release
kinetics (and therefore to underestimate the time for complete drug release) when compared to the
millifluidic device that mimics mouth physiological conditions thanks to the laminar tangential solvent
flow, low flow rates, and low hold-up volume.
Figure 10A shows integral release curves Mt/M∞ vs. t (min) as obtained with the USP II apparatus
and with the MFTD with flow rates Q = 1, 2, 4, 5 mL/min. No error bars for MFTD data (repeated in
triplicate) are reported because of the large amount of data (output drug concentration is recorded
every 2 s from the UV/Vis analyzer), but the maximum standard deviation is an order of 10%, i.e.,
cs(ti) = cs(ti)(1± 0.1), where cs(ti) represents the output concentration at time instant ti, averaged
over three repeated experiments.
It should be observed that release curves from the MFTD are extremely sensitive to initial film
thickness L0. The larger L0, the larger the release time scales, for the same solvent flow rate. Release
curves in the MFTD are also extremely sensitive to the solvent flow rate Q. The larger Q is, the smaller
the mass-transfer resistance is at the gel-solvent interface and therefore the faster the release is. Actually,
for very high flow rates (Q > 12 mL/min), the dissolved drug is immediately swept away by the
solvent flow, and diffusion through the polymeric matrix becomes the controlling step. At this point,
any further increase in the flow rate does not improve drug release.
Release curves shown in Figure 10 seem not to follow the expected behavior (the larger Q is,
the faster the release is) only because different experiments for different flow rates are characterized
by significantly different average film thicknesses L0. For example, L0 ' 70 µm for Q = 2, while
L0 ' 90 µm. For this reason, in order to make release data independent of the film thickness and to
observe the expected behavior as a function of the flow rate Q, we choose, analogously to what has
been done in Section 4.4 with swelling-erosion data, to represent release curves as a function of the
dimensionless time τ = t/tre f , tre f being the characteristic swelling time tre f = L20/D
s
G.
Figure 10B shows the same integral release curves shown in Figure 10A but plotted as a function
of the dimensionless time τ. We can readily observe that release data from USP II apparatus are
significantly faster than that obtained in the MFTD and that release data from the MFTD follow the
expected behavior as a function of Q. The same phenomenon is observed for release data from films
including HP-β-CD, as shown in Figure 10C.
In Figures 10B,C, we also show integral release curves as obtained from the numerical solution of
theoretical models for USP II and MFTD described in Sections 3.3 and 3.4. All parameters entering the
models, namely D f0 , D
f+CD
0 , D
f
G, and D
f+CD
G are the same as estimated from release data in the Franz
cell (reported in Table 2). The only parameter left as a best fitting parameter is the constant C [µm/s]
entering the disentanglement rate equation (Equation (8)) in the swelling-erosion model, because it
depends on the fluid dynamic conditions occurring in the dissolution apparatus.
We expect that erosion, quantified by the disentanglement rate, is maximum in the USP II
apparatus and that Rdis increases with the flow rate Q in the MFTD, because the larger the flow rate is,
the larger the shear stress at the gel-solvent interface is (see Figure 11 for a detail of erosion effect on
a film after complete release in the MFTD). This is confirmed by the analysis of the disentanglement
rate Rdis estimated from a best fit of experimental release data and reported in Table 3. Erosion is also
responsible for the “wavy” behavior of the MFTD release curves due to the possible detachment of
small pieces of film that can affect UV/Vis detection of drug concentration.
The agreement between model prediction and experimental data is quite satisfactory for both films
with and without HP-β-CD. In agreement with swelling-erosion experiments, drug release is faster for
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films with HP-β-CD due to larger erosion effects. For both films the release in USP II apparatus is at
least twice as fast as that in MFTD at an intermediate salivary flow rate Q = 2, 3 mL/min.
Figure 11. Detail of erosion effect on a film after complete release in the MFTD. The portion of the film
exposed to the solvent is completely removed at the end of the experiment.
Table 3. Disentanglement rate (µm/s) for release experiments in USP II apparatus and in MFTD at
different flow rates.
Rdis (µm/s) 1 (mL/min) 2 (mL/min) 4 (mL/min) 5 (mL/min) USP II
without HP-β-CD 0.26 0.32 0.41 0.5 0.64
with HP-β-CD 0.38 0.47 0.61 0.74 0.96
5. Conclusions
In this work, hydroxypropylmethyl cellulose (HPMC) fast-dissolving thin films containing
hydroxypropyl-β-CD are proposed as suitable formulations for furosemide oral drug delivery.
Three different apparatuses, namely the Franz cell, the millifluidic flow-through device, and the
USP II paddle type dissolution apparatus, were used and the results compared.
In particular, we propose an original use of the Franz cell as a release apparatus for estimating the
effective drug diffusion coefficient in the swollen film, especially when, as in the present case, OTFs
exhibit rapid disintegration (strong erosion effects).
The millifluidic flow-through device, specifically designed to mimic mouth physiological
conditions, allowed us to estimate drug release time scales at solvent flow rates comparable
with salivary flow rates and to observe significant and expected differences with release time
scales estimated with official methods, e.g., the USP II apparatus, actually designed for mimic the
gastrointestinal tract.
Swelling-erosion data show that OTFs undergo a rapid swelling and erosion. Release data in
MFTD and USP II show that OTFs exhibit fast release, enhanced by rapid dissolution.
In agreement with swelling-erosion experiments, furosemide release is faster for films including
HP-β-CD due to larger erosion effects. For both films, with and without HP-β-CD, the release
in USP II apparatus is at least twice faster than release in MFTD at an intermediate salivary flow
rate Q = 2, 3 mL/min, thus confirming that official USP II apparatus tends to overestimate the
release kinetics.
Mathematical models adopted allowed us to estimate all the diffusion coefficients required for an
accurate description of drug release in MFTD and USP II.
The agreement between model predictions and experimental data is quite satisfactory for
both films with and without HP-β-CD. The erosion effect, quantified by the disentanglement rate,
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is influenced by the fluid dynamic conditions characterizing the release apparatus. It is maximum in
the USP II apparatus and increases with the flow rate Q in the MFTD.
Although mucoadhesion tests should be performed in order to verify if the residence time “in situ”
of the formulation is comparable with that required for drug release, the analysis reported and the
results obtained showed that HPMC-based thin films represent a valid drug delivery and fast release
formulation.
Supplementary Materials: The following are available at www.mdpi.com/xxx/s1, Figure S1: Flow curves of the
film-forming solutions, Figure S2: Puncture strength (A) and elongation to break (B) of OTFs with and without
HP-β-CD.
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